New drug trial targets Tough-to-Treat lung cancer mutations
NCT ID NCT07336732
Summary
This study is testing a new targeted drug called andamertinib, given alone or with standard chemotherapy, for people with advanced non-small cell lung cancer. It is for patients who have a specific, less common type of genetic change (atypical EGFR mutation) and have not yet received treatment for their advanced cancer. The goal is to see if the new drug combination is more effective and safe than chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.